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in a high-risk cohort of patients with known or suspected coronary artery disease. This
prospective, single-center study included 3,381 patients who underwent DSE from January
1990 to January 2003. Two-dimensional echocardiographic images were acquired at rest,
during dobutamine stress, and during recovery. Follow-up events were collected and
included overall mortality, cardiac death, nonfatal myocardial infarction, and revascular-
ization. The incremental value of DSE in the prediction of selected end points was evalu-
ated using multivariate Cox proportional hazard analysis. During a mean follow-up of 13 –
3.2 years (range 7.3 to 20.5 years), there were 1,725 deaths (51%), of which 1,128 (33%) were
attributed to cardiac causes. Patients with an abnormal DSE had a higher mortality rate
(44% vs 35% at 15-year follow-up, p <0.001) than those with a normal DSE. When
comparing echocardiographic variables at rest to variables at maximum dose dobutamine,
the chi-square of the test improved from 842 to 870 (p <0.0001) and from 684 to 740
(p <0.0001) for all-cause mortality and cardiac death, respectively. DSE provided incre-
mental value in predicting all-cause mortality, cardiac death, and hard cardiac events.
There seems, however, to be a “warranty period” of approximately 7 years, when the
survival curves of a normal and abnormal DSE no longer diverge.  2016 The Authors.
Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/). (Am J Cardiol 2016;117:1078e1083)Exercise electrocardiography is the most frequently used
method for noninvasive evaluation of coronary artery disease
(CAD). Still, a substantial number of patients have an
impaired exercise capacity, because of a weak general
physical condition, neuropathy, or peripheral vascular dis-
ease. Dobutamine stress echocardiography (DSE) has been
reported as a safe1 and effective noninvasive tool to provide
diagnostic and prognostic information in various clinical
scenarios.2e7 Currently, it is not known whether the prog-
nostic value of DSE in patients with limited exercise capacity
is preserved at very long-term (>10 years) follow-up. The
goals of this study were to assess the very long-term outcome
after DSE in a high-risk group of consecutive patients and to
evaluate whether DSE has incremental prognostic value over
clinical variables and echocardiographic data at rest.
Methods
This prospective study included 3,875 consecutive pa-
tients at high risk with known or suspected CAD, who were
unable to perform an adequate exercise test. Indications for
DSE were diagnosis of CAD (54%), preoperative evaluation
before noncardiac surgery (34%), and risk stratiﬁcation afterf Cardiology, Thoraxcenter, Erasmus Medical Center,
Netherlands. Manuscript received October 16, 2015;
t received and accepted January 7, 2016.
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0.1016/j.amjcard.2016.01.002myocardial infarction (MI, 12%). Of all patients who un-
derwent DSE, 30% had a history of typical angina, and 13%
had a history of atypical angina.8 Data were collected from
patients who underwent DSE from January 1990 to January
2003 at the Thoraxcenter, Rotterdam, the Netherlands.
Follow-up data at shorter intervals and of speciﬁc subgroups
of this study cohort have been previously published.2,5,9
Thirty-nine patients were lost to follow-up, and 455 pa-
tients underwent early coronary revascularization in the ﬁrst
60 days after DSE and were excluded from the analysis
because referral for revascularization within this period is
likely to be based on DSE results. The ﬁnal population of
this study consisted of 3,381 patients. This study was not
subject to the Dutch Medical Research Involving Human
Subjects Act. Therefore, approval from the local research
ethics committee to conduct this prospective follow-up
study was not required at the time of enrollment. The
study was conducted according to the Declaration of Hel-
sinki.10 All patients consented participation in this study.
Clinical characteristics including hypertension, hyper-
cholesterolemia, smoking, previous MI, a history of heart
failure, and/or revascularization were recorded at the time of
DSE in a computerized database. Hypertension was deﬁned
as systolic blood pressure 140 mm Hg, diastolic blood
pressure 90 mm Hg, or the use of antihypertensive
medication. Hypercholesterolemia was deﬁned as total
cholesterol >200 mg/dl or the use of cholesterol-lowering
agents. Heart failure was deﬁned according to the New
York Heart Association classiﬁcation and based on estab-
lished guidelines at the time of diagnosis.11ccess article www.ajconline.org
Table 1
Clinical characteristics
Variable n ¼ 3,381
Men 2,275 (67%)
Age (yrs) 61.4  12
Hypertension 1,005 (30%)
Hypercholesterolemia 770 (23%)
Smoking 988 (29%)
Diabetes mellitus 378 (11%)
Heart failure 454 (13%)
Coronary artery disease 1,525 (45%)
Beta-blockers 1,116 (33%)
Calcium-channel blockers 816 (24%)
Angiotensin-converting-enzyme inhibitor 845 (25%)
Diuretics 477 (14%)
Nitrates 1,031 (31%)
Coronary Artery Disease/Long-Term Follow-Up of DSE 1079After baseline echocardiography, dobutamine was
infused at a starting dose of 5 mg/kg/min for 3 minutes
followed by 10 mg/kg/min for 3 minutes (low-dose stage).
The dobutamine dose was increased by 10 mg/kg/min every
3 minutes up to a maximum dose of 40 mg/kg/min. Atropine
(up to 1 mg) was administered intravenously at the end of
the last stage if the target heart rate was not achieved. End
points of the test were an achievement of the target heart rate
(85% of the maximal heart rate predicted for age), the
maximal dose of dobutamine and atropine, >2 mV down-
sloping ST-segment depression measured 80 ms from the J
point compared with baseline, hypertension (blood pressure
>240/120 mm Hg), a decrease in systolic blood pressure of
>40 mm Hg, and signiﬁcant arrhythmias.
Two-dimensional echocardiographic images were ac-
quired at rest, during dobutamine stress, and during recovery
using standard views. Regional wall motion and systolic
wall thickening were scored on a 5-point scale using a
standard 16-segment left ventricular model. Ischemia was
deﬁned as new or worsened wall motion abnormalities
(WMA) during stress indicated by an increase of wall mo-
tion score 1 grade in 1 segment. A biphasic response in
an akinetic or severely hypokinetic segment was considered
as an ischemic response. Ischemia was not considered pre-
sent when akinetic segments at rest became dyskinetic
during stress.12 For each patient, a wall motion score index
(WMSI) was calculated by dividing the sum of segment
scores by the total number of interpreted segments. The test
was considered abnormal if WMA were seen either at rest or
during stress.
Outcome data were obtained by a questionnaire, evalu-
ation of hospital records, contacting the patient’s general
practitioner, and/or review of civil registries. The cause of
death was retrieved at Statistics Netherlands (www.cbs.nl).
This permitted high accuracy for determination of survival
status. Deaths were classiﬁed as either documented cardiac
death or other. Before contacting the patient, the online
municipal civil registry was used to determine the patient’s
present survival status. Survival status was retrieved in 99%
of the patients. Questionnaires were sent to all patients alive.
The response rate of this questionnaire was 83%. The date
of response was used to calculate follow-up time. Follow-up
events noted were overall mortality, hard cardiac events
(non-fatal MI and cardiac death), and revascularization.
Continuous data are expressed as mean values  SD. The
Student t test was used to analyze continuous data, and the
chi-square test was used for differences between pro-
portions. The incremental value of DSE over the clinical
variables in the prediction of selected end points was eval-
uated using multivariate Cox proportional hazard analysis
(SPSS Software, version 21.0) including a model with
baseline characteristics and clinical variables. Only variables
that were signiﬁcant in a univariate model were added to the
multivariate model. Using a stepwise model, echocardio-
graphic variables at rest were then added to the clinical
model to investigate the increase in chi-square value of the
model. Finally, the variables at peak-dose dobutamine were
added to the model. The test was considered of additional
value if there was a signiﬁcant increase in chi-square value
at the third step of the test. The echocardiographic variables
that were added at rest and peak-dobutamine dose wereheart rate, systolic and diastolic blood pressure, rate pressure
product (deﬁned as maximum heart rate times the maximum
systolic blood pressure), WMSI, and WMA. The probability
of survival was calculated using the KaplaneMeier method,
and survival curves were compared using the log-rank test.
To determine the warranty period of DSE, the Cox pro-
portional hazard analysis for an abnormal DSE was repeated
at 1, 2, 3, and so on years of follow-up. A p value <0.05
was considered statistically signiﬁcant.
Results
Mean age at time of DSE was 61  12 years. There were
2,275 men (67%) and 1,106 women (33%). Forty-ﬁve
percent of the patients had known CAD. Clinical charac-
teristics are presented in Table 1. The test was terminated for
achievement of the target heart rate in 89% of the patients,
maximal dobutamine/atropine dose in 3%, ST-segment
changes in 3%, arrhythmias in 1%, severe angina in 1%,
abnormal blood pressure in 1%, and other symptoms in 2%.
Five hundred sixty-eight (17%) patients had typical angina
during dobutamine stress.
DSE was normal in 1,170 of the patients (35%). Ischemia
on DSE was detected in 1,610 patients (48%); of which
1,441 (90%) had WMA at rest. Six hundred one (18%)
patients had WMA at rest alone. During a mean follow-up
of 13  3.2 years (range 7.3 to 20.5 years), there were
1,725 deaths (51%), of which 1,128 (33% of total study
cohort) were attributed to cardiac causes. Two hundred
ninety-seven patients (8.8%) had a nonfatal MI, and 793
patients were revascularized (23.5%) at during follow-up.
The annualized mortality rate of patients who underwent
revascularization after an ischemic event was comparable to
the group who did not undergo percutaneous coronary
intervention (3.9% vs 4.2%, respectively).
Cumulative survival curves (Figure 1) showed a signiﬁ-
cantly better survival of patients with normal DSE in com-
parison with abnormal DSE (76% vs 69% at 5 years, 57% vs
50% at 10 years, and 44% vs 35% at 15 years; overall
p <0.001). Figure 1 illustrates that also for the end points
cardiac death (87% vs 77% at 5 years, 74% vs 62% at
10 years, and 63% vs 47% at 15 years; overall p <0.001)
and hard cardiac events (82% vs 69% at 5 years, 65% vs
Figure 1. KaplaneMeier survival curves for all-cause mortality (A), cardiac
death (B), and hard cardiac events (C) in patients with normal (dark gray)
versus abnormal (light gray) DSE. The dummy lines illustrate that the
curves start to run parallel at approximately 7 years (dashed line).
1080 The American Journal of Cardiology (www.ajconline.org)51% at 10 years, and 52% vs 34% at 15 years; overall p
<0.001), the population with a normal DSE had signiﬁcant
lower chance of adverse events.
Univariate and multivariate predictors associated with an
increased risk of all end points of interest are presented in
Tables 2 and 3. Echocardiographic variables at peak-dose
dobutamine signiﬁcantly increased the value of the test for
all end points. When comparing echocardiographic vari-
ables at rest to variables at maximum dose dobutamine,
the chi-square of the test improved from 842 to 870
(p <0.0001) and from 684 to 740 (p <0.0001) for all-cause
mortality and cardiac death, respectively. WMSI during
stress predicted both all-cause mortality and cardiac death.
At 5 years of follow-up, the hazard ratio of having an
abnormal DSE reached a maximum of 1.37 and started to
decrease after 7 years of follow-up.
Discussion
DSE is a commonly used tool to predict short to medium-
term outcome of patients with limited exercise capacity. In
this high-risk patient cohort, DSE has incremental value at
very long-term follow-up for predicting all end points of
interest in a consecutive population with known or sus-
pected CAD. DSE added prognostic value to clinical vari-
ables and stress test data in predicting all-cause mortality,
cardiac death, and hard cardiac events. Heart rate, WMSI,
and new or worsened WMA during peak-dose dobutamine
were signiﬁcant predictors depending on the end points of
interest (Tables 2 and 3). KaplaneMeier curves conﬁrmed
the previously described ﬁndings because outcome for all
end points of interest was in favor of a normal DSE in
comparison with an abnormal DSE at 18 years after initial
testing (p <0.001).
Although the KaplaneMeier curves showed a signiﬁcant
improved outcome in favor of a normal DSE for all end
points, it is of interest to see that the curve of all-cause
mortality (Figure 1) diverges up to approximately 7 years
after DSE. At this point, the test seems to stop to further
discriminate between abnormal and normal DSE and both
lines start to run parallel. This effect is less pronounced in
the KaplaneMeier curves of cardiac death (Figure 1) and
hard cardiac events (Figure 1), but it suggests a certain
“warranty period” of a DSE. This in line with what we
observed in the diabetic subcohort of this population,5
where a similar phenomenon was observed at 7 years.
The prognostic signiﬁcance of DSE at short- to medium-
term follow-up has been demonstrated in several stud-
ies.13e17 Currently, there are no studies evaluating the very
long-term prognostic role of DSE. In a meta-analysis, Shaw
et al18 investigated the prognostic role of dipyridamole and
DSE in preoperative screening before vascular surgery. The
meta-analysis included 15 studies, of which 5 studies
(n ¼ 445) were based on studies on DSE. The analysis
demonstrated that echocardiographic WMA were predictive
of adverse perioperative outcomes. Their analysis supports
pharmacologic stress imaging as a tool for preoperative
screening in patients at intermediate risk. These previous
studies provide useful information about the clinical
importance of DSE, but the very long-term prognostic value
of a DSE remains unclear. This study provides unique
Table 2
Independent predictors of all-cause mortality
Univariate (1):
Clinical
(2):
(1) þ DSE At Rest
(3):
(2) þ DSE At Peak
HR (CI) HR (CI) HR (CI)
Male gender 1.45 (1.31-1.62) 1.39 (1.25-1.55) 1.39 (1.25-1.55) 1.38 (1.23-1.54)
Age 1.06 (1.05-1.06) 1.06 (1.05-1.06) 1.06 (1.06-1.07) 1.06 (1.06-1.07)
Coronary artery disease Not signiﬁcant - - -
Heart failure 1.91 (1.68-2.17) 1.59 (1.38-1.82) 1.36 (1.18-1.58) 1.40 (1.21-1.62)
Diabetes mellitus 1.44 (1.25-1.65) 1.49 (1.30-1.72) 1.41 (1.22-1.62) 1.40 (1.21-1.61)
Hypertension Not signiﬁcant - - -
Hypercholesterolemia 0.71 (0.62-0.80) 0.74 (0.65-0.84) 0.68 (0.60-0.77) 0.69 (0.60-0.78)
Smoking 1.24 (1.12-1.37 1.42 (1.28-1.57) 1.42 (1.28-1.58) 1.42 (1.28-1.58)
Beta-blockers 0.81 (0.73-0.89) 0.86 (0.77-0.96) Not signiﬁcant -
Calcium-channel blockers Not signiﬁcant - - -
Angio-converting enzyme inhibitors 1.29 (1.16-1.43) Not signiﬁcant - -
Diuretics 1.73 (1.53-1.97) 1.33 (1.15-1.53) 1.23 (1.07-1.42) 1.23 (1.07-1.42)
Digoxin 2.24 (1.88-2.68) 1.36 (1.12-1.65) Not signiﬁcant -
Nitrates Not signiﬁcant - - -
Heart rate rest 1.11 (1.07-1.15) - 1.13 (1.09-1.18) Not signiﬁcant
Systolic blood pressure rest 1.05 (1.03-1.07) - Not signiﬁcant -
Diastolic blood pressure rest Not signiﬁcant - - -
Rate pressure product rest 1.01 (1.00-1.01) - Not signiﬁcant -
Wall motion score index rest 1.48 (1.38-1.59) - 1.32 (1.22-1.44) Not signiﬁcant
Rest wall motion abnormalities 1.29 (1.17-1.42) - Not signiﬁcant -
Heart rate peak 0.97 (0.95-0.99) - - Not signiﬁcant
Systolic blood pressure peak 0.97 (0.95-0.99) - - Not signiﬁcant
Diastolic blood pressure peak 0.95 (0.92-0.98) - - Not signiﬁcant
Rate pressure product peak 1.00 (1.00-1.00) - - Not signiﬁcant
Wall motion score index peak 1.54 (1.43-1.67) - - 1.35 (1.23-1.48)
Peak wall motion abnormalities 1.37 (1.25-1.51) - - Not signiﬁcant
Any wall motion abnormalities 1.27 (1.15-1.41) - - Not signiﬁcant
X2-test 842 870 870
p-value - P < 0.0001 P < 0.0001
Coronary Artery Disease/Long-Term Follow-Up of DSE 1081information on the very long-term prognostic value of the
test in a consecutive population of subjects with known or
suspected CAD. It demonstrates the clinical importance of
DSE results for assessment of very long-term outcome.
The event rate in this present study is high (51% of the
patients died during follow-up). There are multiple factors
that may explain the relatively high event rate in this study.
First, this cohort is a high-risk group, the mean age was
61 years and 45% had known CAD, whereas 65% of the
patients had an abnormal DSE. Second, all patients under-
went DSE because of limited exercise capacity. The
inability to perform an adequate exercise test is an indicator
of adverse outcome in itself. Third, the follow-up of this
cohort was nearly complete. Finally, this study has follow-
up period of >10 years, which is signiﬁcantly longer than
previous studies.
Although this study included a high-risk population,
Table 1 demonstrates that patients seemed undertreated ac-
cording to current standards. Inclusion of patients in this
study started as early as 1990, a time at which medical
treatment was suboptimal compared with current standards,
as has been demonstrated in the EUROASPIRE (EURO-
pean Action on Secondary and Primary prevention through
Intervention to Reduce Events) registry.19 Referral to cor-
onary revascularization (23.5%) was also relatively low
given the 48% of the patients with detected ischemia.However, previous studies have demonstrated that the
timing of revascularization requires careful consideration.20
Patients with no or mild symptoms and little ischemia can
safely be treated with medical treatment alone. Furthermore,
the COURAGE (Clinical Outcomes Utilizing Revasculari-
zation and Aggressive Drug Evaluation) trial21 has demon-
strated that clinical outcome in patients with stable angina
does not signiﬁcantly differ between patients who receive an
initial therapy of coronary revascularization and optimal
medical therapy compared to patients with optimal medical
therapy alone.
The American College of Cardiology recommends
pharmacologic stress with either nuclear myocardial infu-
sion imaging or echocardiography for risk assessment in
patients with stable ischemic heart disease who are either
unable to exercise to an adequate workload regardless of
interpretability of electrocardiogram, patients with left
bundle branch block on electrocardiogram regardless of
ability to exercise to an adequate workload or patients who
are being considered for revascularization of known coro-
nary stenosis of unclear physiological signiﬁcance.22 The
appropriateness criteria for stress echocardiography formu-
lated by the American College Cardiology illustrate these
recommendations and add several clinical scenarios in
which stress echocardiography is the preferred technique or
can be considered.23 The present study demonstrates that
Table 3
Independent predictors of cardiac death
Univariate (1):
Clinical
(2):
(1) þ DSE At Rest
(3):
(2) þ DSE At Peak
HR (CI) HR (CI) HR (CI) HR (CI)
Male gender 1.56 (1.36-1.78) 1.46 (1.27-1.67) 1.40 (1.22-1.61) 1.38 (1.20-1.59)
Age 1.07 (1.05-1.05) 1.06 (1.06-1.07) 1.06 (1.06-1.07) 1.06 (1.05-1.07)
Coronary artery disease 1.33 (1.18-1.50) Not signiﬁcant - -
Heart failure 2.47 (2.14-2.86) 2.00 (1.70-2.35) 1.60 (1.36-1.89) 1.65 (1.40-1.94)
Diabetes mellitus 1.40 (1.17-1.67) 1.42 (1.19-1.70) 1.32 (1.11-1.58) 1.30 (1.09-1.56)
Hypertension Not signiﬁcant - - -
Hypercholesterolemia 0.78 (0.67-0.90) 0.80 (0.69-0.94) 0.72 (0.62-0.84) 0.73 (0.63-0.86)
Smoking 1.36 (1.20-1.54) 1.54 (1.36-1.74) 1.54 (1.35-1.74) 1.53 (1.35-1.73)
Beta-blockers 0.81 (0.71-0.92) 0.86 (0.75-0.98) Not signiﬁcant -
Calcium-channel blockers Not signiﬁcant - - -
Angio-converting enzyme inhibitors 1.48 (1.30-1.68) Not signiﬁcant - -
Diuretics 1.95 (1.67-2.26) 1.34 (1.12-1.59) Not signiﬁcant -
Digoxin 2.68 (2.18-3.28) 1.46 (1.17-1.83) 1.36 (1.09-1.70) 1.33 (1.06-1.66)
Nitrates 1.32 (1.16-1.49) Not signiﬁcant - -
Heart rate rest 1.12 (1.06-1.17) - 1.13 (1.08-1.18) 1.14 (1.09-1.19)
Systolic blood pressure rest 1.03 (1.01-1.06) - Not signiﬁcant -
Diastolic blood pressure rest Not signiﬁcant - - -
Rate pressure product rest 1.01 (1.00-1.01) - Not signiﬁcant -
Wall motion score index rest 1.78 (1.64-1.94) - 1.54 (1.39-1.69) Not signiﬁcant
Rest wall motion abnormalities 1.70 (1.50-1.93) - Not signiﬁcant -
Heart rate peak 0.96 (0.94-0.99) - - Not signiﬁcant
Systolic blood pressure peak 0.95 (0.93-0.97) - - Not signiﬁcant
Diastolic blood pressure peak 0.93 (0.89-0.96) - - Not signiﬁcant
Rate pressure product peak 1.00 (0.99-1.00) - - Not signiﬁcant
Wall motion score index peak 1.93 (1.77-2.12) - - 1.63 (1.47-1.81)
Peak wall motion abnormalities 1.76 (1.57-1.99) - - Not signiﬁcant
Any wall motion abnormalities 1.70 (1.49-1.94) - - Not signiﬁcant
X2-test - 684 734 740
p-value - - P <0.0001 P <0.0001
1082 The American Journal of Cardiology (www.ajconline.org)DSE is a valuable test in predicting all-cause mortality,
cardiac death, and hard cardiac events, even at very long-
term follow-up. The long-lasting follow-up of this study is
unique and reinforces the ﬁnding from shorter follow-up
studies that stress echo is a powerful prognostic test.
There seems to be a “warranty period” of approximately
7 years after which a DSE start to lose its ability to further
discriminate between a normal and abnormal DSE.
This study has some limitations. First, because of the
clinical factors leading patients to be referred for DSE at the
time of initial testing, they are likely to have had increased
risk for adverse events with a worse prognosis than a general
population. This may limit application of the present ﬁnd-
ings to patients suspected for CAD in general. Furthermore,
left ventricular ejection fraction was not available in all
patients because it was only measured on indication and
could therefore not be used in the analysis.
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